1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)
Trade Name: Magnesium Sulfate in Water for Injection, USP
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as electrolyte replacement anticonvulsant

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
International CHEMTREC (24 hours): +1-703-527-3887
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification: Not classified as hazardous

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>SULPHURIC ACID ... %</td>
<td>7664-93-9</td>
<td>231-639-5</td>
<td>Skin Corr. 1A (H314) **</td>
<td></td>
</tr>
<tr>
<td>SODIUM HYDROXIDE</td>
<td>1310-73-2</td>
<td>215-185-5</td>
<td>Skin Corr. 1A (H314) **</td>
<td></td>
</tr>
<tr>
<td>Magnesium sulfate heptahydrate</td>
<td>10034-99-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>4-8</td>
</tr>
<tr>
<td>Water for Injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>92</td>
</tr>
</tbody>
</table>

Additional Information: ** to adjust pH
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

** Eye Contact:** Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

** Skin Contact:** Wash skin with soap and water. If skin irritation persists, call a physician.

** Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

** Inhalation:** Move to fresh air. If discomfort persists, get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

** Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

** Medical Conditions Aggravated by Exposure:** None known

Indication of the Immediate Medical Attention and Special Treatment Needed

** Notes to Physician:** None

5. FIRE FIGHTING MEASURES

** Extinguishing Media:** As for primary cause of fire.

** Special Hazards Arising from the Substance or Mixture**

** Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire. Emits oxides of sulfur under combustion.

** Fire / Explosion Hazards:** Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Incompatible Materials: None known
Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

SULPHURIC ACID ... %
ACGIH Threshold Limit Value (TWA) 0.2 mg/m³
Australia STEL 3 mg/m³
Australia TWA 1 mg/m³
Austria OEL - MAKs 0.1 mg/m³
Belgium OEL - TWA 0.2 mg/m³
Bulgaria OEL - TWA 0.05 mg/m³
Cyprus OEL - TWA 0.05 mg/m³
Czech Republic OEL - TWA 1 mg/m³

Denmark OEL - TWA 0.05 mg/m³
Estonia OEL - TWA 1 mg/m³
Finland OEL - TWA 0.05 mg/m³
France OEL - TWA 0.05 mg/m³
Germany - TRGS 900 - TWAs 0.1 mg/m³
Germany (DFG) - MAK 0.1 mg/m³
Greece OEL - TWA 0.05 mg/m³
Hungary OEL - TWA 0.05 mg/m³
Ireland OEL - TWAs 0.05 ppm
Italy OEL - TWA 0.05 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Japan - OELs - Ceilings 1 mg/m³
Latvia OEL - TWA 0.05 mg/m³
Lithuania OEL - TWA 0.05 mg/m³
Luxembourg OEL - TWA 0.05 mg/m³
Malta OEL - TWA 0.05 mg/m³
Netherlands OEL - TWA 0.05 mg/m³
OSHA - Final PELS - TWAs: 1 mg/m³
Poland OEL - TWA 0.05 mg/m³
Portugal OEL - TWA 0.05 mg/m³
Romania OEL - TWA 0.05 mg/m³
Slovakia OEL - TWA 0.1 mg/m³
Slovenia OEL - TWA 0.05 mg/m³
Spain OEL - TWA 0.05 mg/m³
Sweden OEL - TWAs 0.1 mg/m³
Switzerland OEL - TWAs 0.1 mg/m³
Vietnam OEL - TWAs 1 mg/m³

SODIUM HYDROXIDE
ACGIH Ceiling Threshold Limit: 2 mg/m³
Australia PEAK 2 mg/m³
Austria OEL - MAKs 2 mg/m³
Bulgaria OEL - TWA 2.0 mg/m³
Czech Republic OEL - TWA 1 mg/m³
Estonia OEL - TWA 1 mg/m³
France OEL - TWA 2 mg/m³
Greece OEL - TWA 2 mg/m³
Hungary OEL - TWA 2 mg/m³
Japan - OELs - Ceilings 2 mg/m³
Latvia OEL - TWA 0.5 mg/m³
OSHA - Final PELS - TWAs: 2 mg/m³
Poland OEL - TWA 0.5 mg/m³
Slovakia OEL - TWA 2 mg/m³
Slovenia OEL - TWA 2 mg/m³
Sweden OEL - TWAs 1 mg/m³
Switzerland OEL - TWAs 2 mg/m³

Exposure Controls
Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Liquid</th>
<th>Color:</th>
<th>Colourless</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available</td>
<td>Odor Threshold:</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH:</td>
<td>3.5-6.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting/Freezing Point (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SULPHURIC ACID</td>
<td></td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM HYDROXIDE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium sulfate heptahydrate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water for Injection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decomposition Temperature (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evaporation Rate (Gram/s):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vapor Pressure (kPa):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vapor Density (g/ml):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relative Density:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viscosity:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flammability:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoignition Temperature (Solid) (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flammability (Solids):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flash Point (Liquid) (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: None
Conditions to Avoid: None known
Incompatible Materials: None known
Hazardous Decomposition Products: Thermal decomposition products include oxides of sulfur.
11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the active ingredient(s).

Known Clinical Effects: Adverse effects associated with therapeutic use include flushing, sweating, decrease in blood pressure (hypotension), circulatory failure, central nervous system depression.

Acute Toxicity: (Species, Route, End Point, Dose)

Magnesium sulfate heptahydrate
- Rat Oral LD50: 5000 mg/kg
- Mouse Oral LD50: 3000 mg/kg

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Magnesium sulfate heptahydrate
- Fertility and Embryonic Development Rat Oral LD50: 450 mg/kg/day NOAEL: No evidence of impaired fertility or harm to the fetus

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Magnesium sulfate heptahydrate
- Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogen Status: See below. The International Agency for Research on Cancer (IARC) and the United States National Toxicology Program (NTP) have classified 'occupational exposure to strong inorganic acid mists containing sulfuric acid' as a known human carcinogen. This classification applies only to sulfuric acid when generated as a mist. This classification is debated within the scientific community and there is disagreement as to whether or not a cause and effect relationship between cancer and 'occupational exposure to strong inorganic acid mists containing sulfuric acid' exists.

SULPHURIC ACID ... %
- IARC: Group 1 (Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Magnesium sulfate heptahydrate
  CERCLA/SARA 313 Emission reporting: Not Listed
  California Proposition 65: Not Listed
  Australia (AICS): Present
  EU EINECS/ELINCS List: Not Listed

Water for Injection
  CERCLA/SARA 313 Emission reporting: Not Listed
  California Proposition 65: Not Listed
  Inventory - United States TSCA - Sect. 8(b): Present
  Australia (AICS): Present
  REACH - Annex IV - Exemptions from the obligations of Register: Not Listed
  EU EINECS/ELINCS List: 231-791-2

SULPHURIC ACID ... %
  CERCLA/SARA 313 Emission reporting: 1.0 %
  CERCLA/SARA Hazardous Substances and their Reportable Quantities: 1000 lb, 454 kg
  CERCLA/SARA - Section 302 Extremely Hazardous TPDs: 1000 lb
  California Proposition 65: Not Listed
SAFETY DATA SHEET

Material Name: Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)
Revision date: 04-Aug-2016

15. REGULATORY INFORMATION

| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS):                       | Present   |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 6 |
| EU EINECS/ELINCS List                    | 231-639-5 |

SODIUM HYDROXIDE

| CERCLA/SARA 313 Emission reporting       | Not Listed  |
| CERCLA/SARA Hazardous Substances         | 1000 lb     |
| and their Reportable Quantities:         | 454 kg      |
| California Proposition 65                | Not Listed  |
| Inventory - United States TSCA - Sect. 8(b) | Present    |
| Australia (AICS):                        | Present     |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 5 |
| EU EINECS/ELINCS List                    | 215-185-5 |

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage

Data Sources: Publicly available toxicity information.
Revision date: 04-Aug-2016

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet

PZ03097